Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21

Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.
byBenzinga Newsdesk
July 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Medical Marijuana Giant Trulieve, Backer Of Florida’s Recreational Cannabis Ballot, Narrows Loss, Reports Uptick In Q1 Revenue, Gross Profit

By Jelena Martinovic
May 9, 8:49 AM
Trulieve Cannabis Corp. announced on Thursday its first quarter results for the three months ended March 31, 2024. The Tallahassee, Florida-based medical cannabis giant reported revenue of $298 million for the first quarter of fiscal 2024, representing an increase of 4% sequentially and year-over-year, with 96% of revenue from retail sales.

AYRWF